Merck Reports Q1 2026 Earnings with Revenue Growth and Product Performance Highlights
Merck (MRK) reported Q1 2026 revenue of $16.3 billion, a 5% increase, driven by growth in oncology, animal health, and new products. Key products like KEYTRUDA and WELIREG saw strong performance, while GARDASIL faced declines due to reduced demand in key markets.
Tickers: $MRK
Topics: Earnings Report Market Performance Pharmaceutical Industry Product Sales Revenue Growth